ADMA Biologics, Inc., a biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease. The company also operates source plasma collection facilities in Norcross and Marietta, Georgia. In Addition, the company offers Nabi-HB for the treatment of acute exposure; and Bivigam for the treatment of primary humoral immunodeficiency. It distributes its products through independent distributors, sales agents, specialty pharmacies, and others. The ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:ADMA
CUSIPN/A
Phone201-478-5552
Debt
Debt-to-Equity Ratio1.76
Current Ratio4.92
Quick Ratio3.60
Price-To-Earnings
Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A
Sales & Book Value
Annual Sales$22.76 million
Price / Sales9.78
Cash FlowN/A
Price / CashN/A
Book Value$0.89 per share
Price / Book5.52
Profitability
EPS (Most Recent Fiscal Year)($1.91)
Net Income$-43,750,000.00
Net Margins-101.93%
Return on Equity-88.31%
Return on Assets-25.76%
Miscellaneous
Employees295
Outstanding Shares45,320,000
ADMA Biologics (NASDAQ:ADMA) Frequently Asked Questions
What is ADMA Biologics' stock symbol?
ADMA Biologics trades on the NASDAQ under the ticker symbol "ADMA."
How were ADMA Biologics' earnings last quarter?
ADMA Biologics Inc (NASDAQ:ADMA) announced its quarterly earnings results on Monday, May, 14th. The biotechnology company reported ($0.35) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.27) by $0.08. The biotechnology company had revenue of $4.04 million for the quarter, compared to the consensus estimate of $7.47 million. ADMA Biologics had a negative return on equity of 88.31% and a negative net margin of 101.93%. View ADMA Biologics' Earnings History.
When is ADMA Biologics' next earnings date?
What price target have analysts set for ADMA?
3 equities research analysts have issued 1 year target prices for ADMA Biologics' stock. Their forecasts range from $5.00 to $10.00. On average, they anticipate ADMA Biologics' share price to reach $7.50 in the next twelve months. View Analyst Ratings for ADMA Biologics.
Who are some of ADMA Biologics' key competitors?
Some companies that are related to ADMA Biologics include La Jolla Pharmaceutical (LJPC), Heska (HSKA), Voyager Therapeutics (VYGR), Fate Therapeutics (FATE), Novavax (NVAX), Mesoblast (MESO), BioCryst Pharmaceuticals (BCRX), Scholar Rock (SRRK), CASI Pharmaceuticals (CASI), Surface Oncology (SURF), Nightstar Therapeutics (NITE), Vericel (VCEL), NanoString Technologies (NSTG), PDL BioPharma (PDLI) and Adverum Biotechnologies (ADVM).
Who are ADMA Biologics' key executives?
ADMA Biologics' management team includes the folowing people:
- Mr. Adam S. Grossman, Co-Founder, Pres, CEO & Director (Age 41)
- Dr. Jerrold B. Grossman D.P.S., Co-Founder & Vice Chairman (Age 70)
- Mr. Brian Lenz, VP & CFO (Age 46)
- Dr. James Mond, Exec. VP, Chief Scientific Officer & Chief Medical Officer (Age 72)
- Mr. James Hauert, Sr. VP of Commercialization & Strategy
Has ADMA Biologics been receiving favorable news coverage?
Media headlines about ADMA stock have trended somewhat positive on Sunday, Accern Sentiment reports. The research firm identifies positive and negative press coverage by reviewing more than 20 million news and blog sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ADMA Biologics earned a news sentiment score of 0.13 on Accern's scale. They also gave press coverage about the biotechnology company an impact score of 44.16 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the near future.
Who are ADMA Biologics' major shareholders?
ADMA Biologics' stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Millennium Management LLC (0.60%), BlackRock Inc. (0.09%), JPMorgan Chase & Co. (0.09%), Element Capital Management LLC (0.06%) and Spark Investment Management LLC (0.05%). Company insiders that own ADMA Biologics stock include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond and Jerrold B Grossman. View Institutional Ownership Trends for ADMA Biologics.
Which major investors are buying ADMA Biologics stock?
ADMA stock was purchased by a variety of institutional investors in the last quarter, including Millennium Management LLC, JPMorgan Chase & Co., Element Capital Management LLC, Spark Investment Management LLC and BlackRock Inc.. Company insiders that have bought ADMA Biologics stock in the last two years include Adam S Grossman, Brian Lenz, Eric I Richman, James Mond and Jerrold B Grossman. View Insider Buying and Selling for ADMA Biologics.
How do I buy shares of ADMA Biologics?
Shares of ADMA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is ADMA Biologics' stock price today?
One share of ADMA stock can currently be purchased for approximately $4.91.
How big of a company is ADMA Biologics?
ADMA Biologics has a market capitalization of $220.24 million and generates $22.76 million in revenue each year. The biotechnology company earns $-43,750,000.00 in net income (profit) each year or ($1.91) on an earnings per share basis. ADMA Biologics employs 295 workers across the globe.
How can I contact ADMA Biologics?
ADMA Biologics' mailing address is 465 STATE ROUTE 17, RAMSEY NJ, 07446. The biotechnology company can be reached via phone at 201-478-5552 or via email at [email protected]
MarketBeat Community Rating for ADMA Biologics (ADMA)
MarketBeat's community ratings are surveys of what our community members think about ADMA Biologics and other stocks. Vote "Outperform" if you believe ADMA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ADMA will underperform the S&P 500 over the long term. You may vote once every thirty days.
